Literature DB >> 28837384

Adverse Health Outcomes and Associations with Self-Reported General Health in Childhood Lymphoma Survivors.

Inga M R Johannsdottir1,2, Hanne Hamre3, Sophie D Fosså4,5, Jon Håvard Loge5,6, Liv Drolsum5,7, May Brit Lund5,8, Lars Nordsletten5,9, Cecilie Kiserud2.   

Abstract

BACKGROUND: The increased incidence of physical and psychosocial adverse health outcomes (AHOs) in childhood lymphoma survivors (CLSs) is well known, but these AHOs' association with self-reported general health is rarely described. AIM: We explored this association among long-term CLSs.
METHODS: In 124 CLSs (Hodgkin: 81; non-Hodgkin: 43; median age: 33 years), physical AHOs were graded based on slightly modified common toxicity criteria for adverse effects (CTCAE)-4 recommendations (Grade 0-3). Psychosocial AHOs (pain, work inability, fatigue, and mental distress) were mainly assessed by validated patient-reported questionnaires (Grade 0-2). The results were related to contemporary self-reported general health. Statistical significance: p < 0.01.
RESULTS: At least one physical AHO was found in 120 CLSs, being of Grades 1, 2, and 3, respectively, in 43, 43, and 34 survivors. The prevalence of psychosocial AHOs (Grades 1 or 2) was 63%, being Grade 2 in 62 CLSs. The CLSs described their general health as significantly reduced compared with controls, with the greatest reduction for survivors in whom physical AHOs were combined with moderate to severe psychosocial AHOs.
CONCLUSION: Psychosocial more than physical AHOs impact on CLSs' current self-reported general health. Clinicians responsible for follow-up of CLSs should be aware of the strong reduction of contemporary general health by Grade 2 psychosocial AHOs. The study challenges the use of the physician-assessed CTCAE-4 categories in long-term cancer survivors and emphasizes the need to develop instruments, which reflect both physical and psychosocial AHOs in these individuals.

Entities:  

Keywords:  childhood malignant lymphoma; common toxicity criteria; long-term adverse outcomes

Mesh:

Year:  2017        PMID: 28837384     DOI: 10.1089/jayao.2017.0018

Source DB:  PubMed          Journal:  J Adolesc Young Adult Oncol        ISSN: 2156-5333            Impact factor:   2.223


  5 in total

1.  Severe fatigue after treatment for childhood cancer.

Authors:  Sylvia van Deuren; Amilie Boonstra; Eline van Dulmen-den Broeder; Nicole Blijlevens; Hans Knoop; Jacqueline Loonen
Journal:  Cochrane Database Syst Rev       Date:  2020-03-03

2.  Advances in Hodgkin Lymphoma: Including the Patient's Voice.

Authors:  Christine Moore Smith; Debra L Friedman
Journal:  Front Oncol       Date:  2022-02-25       Impact factor: 6.244

3.  Pain in long-term survivors of childhood cancer: A systematic review of the current state of knowledge and a call to action from the Children's Oncology Group.

Authors:  Fiona S M Schulte; Michaela Patton; Nicole M Alberts; Alicia Kunin-Batson; Barbara A Olson-Bullis; Caitlin Forbes; K Brooke Russell; Alexandra Neville; Lauren C Heathcote; Cynthia W Karlson; Nicole M Racine; Courtney Charnock; Matthew C Hocking; Pia Banerjee; Perri R Tutelman; Melanie Noel; Kevin R Krull
Journal:  Cancer       Date:  2020-10-28       Impact factor: 6.860

Review 4.  Recommendations for the surveillance of cancer-related fatigue in childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

Authors:  Salome Christen; Katharina Roser; Renée L Mulder; Anica Ilic; Hanne C Lie; Jacqueline J Loonen; Anneli V Mellblom; Leontien C M Kremer; Melissa M Hudson; Louis S Constine; Roderick Skinner; Katrin Scheinemann; Jordan Gilleland Marchak; Gisela Michel
Journal:  J Cancer Surviv       Date:  2020-08-25       Impact factor: 4.442

5.  Characterizing pain in long-term survivors of childhood cancer.

Authors:  Michaela Patton; Victoria J Forster; Caitlin Forbes; Mehak Stokoe; Melanie Noel; Linda E Carlson; Kathryn A Birnie; Kathleen Reynolds; Fiona Schulte
Journal:  Support Care Cancer       Date:  2021-07-19       Impact factor: 3.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.